StudentShare
Contact Us
Sign In / Sign Up for FREE
Search
Go to advanced search...
Free

Specific Molecular Alteration in Cancer Development - Essay Example

Cite this document
Summary
The essay "Specific Molecular Alteration in Cancer Development" focuses on the critical analysis of the use of the ERBB2 (HER2/NEU) oncogene to describe one specific molecular alteration which plays a role in cancer development, and discusses how it has been exploited to improve cancer treatment…
Download full paper File format: .doc, available for editing
GRAB THE BEST PAPER98.2% of users find it useful
Specific Molecular Alteration in Cancer Development
Read Text Preview

Extract of sample "Specific Molecular Alteration in Cancer Development"

Sur Lecturer Using either the BCR-ABL oncogene or the ERBB2 (HER2/NEU) oncogene as your example, describe one specific molecular alteration which plays a role in cancer development, and discuss how it has been exploited to improve cancer treatment. 1. Target identification: Identification of the molecular defect in cancer. Previous research into lung carcinoma led to the discovery of ERBB2 analogous mutations. Further research indicated that two to four percent of patients exhibited ERBB2 kinase domain mutations. These mutations contributed to increased invasiveness and survival as well as tumorigenicity especially in the cell based transformational assays. The pathological and clinical characteristics of the patients presenting with ERBB2 mutations tend to be more associated with the female gender patients, nonsmokers, patients of Asian origin as well as the adenocarcinoma subtype. This tends to mimic findings on the NSCLC prompted by EGFR mutations (Yarbro, Debra and Barbara, 15). The discovery on activation of mutations amidst the kinase domain in the ERBB2 offers additional therapeutic opportunities and possibilities. Upon conducting an experiment. Researchers noted that mutations of the ERBB2 would be insignificantly influenced by EGFR-TKIs. Conversely, ERBB2-directed TKIs depicted properties of anti-proliferation. Neratinib(HKI-272) had restored hope in the ERBB2-mutant NCI-H1781 cell lineup with preclinical data however, the resultant evaluation of registered a different finding. Patients presenting with EGFR that drives lung cancers were used in the noted evaluation whereby the findings indicates lack of support for the single agent inhibitor(McKinnell, Parchment, Perantoni, Pierce and Ivan, 23). Competitive inhibitors such as the TKIs prevent the ATP form attaching onto its natural site. This occurs because the small molecules TKIs portray higher affinity to ATP binding site within the kinase region. TKIs within the ERBB molecules can be categorized broadly into reversible and irreversible inhibitors. The reversible inhibitors include lapatinib, erlotinib and gefitinib. They can be produced from the receptors. On the other hand, the irreversible inhibitors include afatinib, dacomitib, pelitinib and neratinib. These inhibitors modify the receptors covalently (McKinnell, Parchment, Perantoni, Pierce and Ivan, 24) 2. Target validation: Characterization of the biological role of the molecular defect in cancer development. In part as a result of the constitutive active formation of the ERBB2 could be preferred as the dimerization associate for the rest of the family members of the ERBB. The ERBB2 heterodimers exhibit higher potency for transmitting signals from the extracellular sources. These potency occur despite the availability of four receptors. The functions of these receptors mainly involve allowing numerous pairings which contributes towards unit patterns in the pathways of downstream engagement. The most significant signaling heterodimer, composed of both the ERBB3 and ERBB2, operates as the oncogenic unit. Absence of the catalytic activity of the kinase allows the ERBB3 to heterodimerize with the other ERB molecules. Primarily, the fundamental signaling tool for the ERBB2-ERBB3may be inevitable for the vital activation of the PI3K/Akt pathway. Essentially ERBB2 lacks a direct docking position for PI3K. On the other hand, ERBB3 operates the function of docking on six binding positions of tyrosine the supervisory subunit of P13K. Research conducted previously on this topic indicates a positive correlation between higher activation of Akt and ERBB2 in breast cancers (Aggarwal, Young and Shishir, 100) Through research, oncogenic activation of ERBB2 present with three principal mechanisms which have been identified in the contemporary world. These mechanisms include amplification and overexpression, molecular alterations in the receptors and inhibition of phosphatase activity. The rising number of receptor molecules for cell surface which populate tend to increase the opportunities for phosphorylation of receptor tyrosine and dimerization. This functions could take place in the presence or absence of ligand binding. Amplification and overexpression of the ERBB2 tend to be associated with highly aggressive tumors and poor outcome (Adjei and John, 67) 3. Drug discovery: Development of therapeutic agents targeted against the molecular defect Evolution of sequencing technology in the current world contributes to successful defeat over the challenges of scale and cost in research. In addition, these advances have enabled researchers to identify thousands of operative mutation activities in the somatic cells in one cancer sample. In bioinformatics algorithms, can progressively help towards exploring on the mutational signature landscapes when combined with intense parallel sequencing. Additionally, this combination could aid in distinguishing further on the passenger mutations from the driver mutations. This functions can be determined through molecular sequencing in an individual’s DNA. The DNA can be obtained from tumor biopsy specimens in order to ascertain the alterations in the genetic and epigenetic makeup of the specimen. Any alterations observed needs to be analyzed further so as to determine the time of clinical appearance as well as the time of resistance to therapy or medication. Furthermore, newer therapeutic targets may have been achieved following intensive multiple fusion in the genes in numerous cancers. These targets arise as a consequence for the major advances in addition to the high output technics and mechanisms such as the wholesome genome sequencing. Nevertheless, analysis and implementation of findings and recommendation obtained from the consortia of gene sequencing may require more intensive or comprehensive efforts in multi-disciplinary efforts in translation into the clinic (Cavalli,80) 4. Clinical application: Use of the novel therapy in the treatment of cancer. For solid cancers cases, the initial targeted molecular antibodies may be directed towards the epitopes of the actual cancer cells involved the anti-EGFR (ErbB1) as well as the Trans membrane RTKs and the anti HER2 (ErbB2). The contrastingly partially potential of the unmet therapies target at EGFR, therapies targeted as HER-2 have led to the revolutionized treatment among fifteen to thirty percent of patients of breast cancers. These therapies contribute to the harboring and amplification of the ERBB2 gene as well as an overexpression of the HER-2 protein. In the previous eras where therapies focused on the HER-2 therapies, breast cancers associated with the amplified ERBB2continuously contributed to a specific poor prognosis. . Trastuzumab (Herceptin®; Genentech: San Fransisco, CA, USA) became the first humanized mAb to be approved in 1998 by FDA despite the interference with with the HER2/ Neu receptor (Walker and Ralph 64)  Since then, major progresses and impacts have been made in the management of HER2-positive breast cancers through adjuvant therapy. In its early stages, stage 0-3, the HER-2-positive breast cancers tend to present a quite positive reaction to Trastuzumab. Furthermore, research indicates that nearly fifty percent of all the HER-2-positive breast cancers being treated with Tarstuzumab do not get the tumors or recurrent tumors. However, in metatstaci breast cancer, acquired resistance or innate resistance which often occur in nearly all the cases reported pose a big challenges. These challenges often tend to be common among the various types of oncology therapies and management. Recently, a more advanced version of the Trastuzumab, trastuzumabemtansine (T-DM1, Kadkyla®; Genentech), can now be accesed for metastatic HER2-positive breast cancers (Vegf and Cancer, 50) Work cited Adjei, Alex A, and John K. Buolamwini. Novel Anticancer Agents: Strategies for Discovery and Clinical Testing. Amsterdam: Academic, 2006. Internet resource. Aggarwal, Bharat B, Young-JoonSurh, and ShishirShishodia. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. New York, NY: Springer, 2007. Internet resource. Cavalli, Franco. Textbook of Medical Oncology. London: informa healthcare, 2009. Print. McKinnell, Robert G, Ralph E. Parchment, Alan O. Perantoni, G B. Pierce, and Ivan Damjanov. The Biological Basis of Cancer. Cambridge: Cambridge University Press, 2006. Internet resource. Vegf and Cancer. Springer Verlag, 2013. Print. Walker, John M, and Ralph Rapley. Molecular Biomethods Handbook. Totowa, NJ: Humana Press, 2008. Internet resource. Yarbro, Connie H, Debra Wujcik, and Barbara H. Gobel. Cancer Nursing: Principles and Practice. Sudbury, Mass: Jones and Bartlett Publishers, 2011. Print. Read More
Cite this document
  • APA
  • MLA
  • CHICAGO
(“Using either the BCR-ABL oncogene or the ERBB2 (HER2/NEU) oncogene as Essay”, n.d.)
Retrieved from https://studentshare.org/miscellaneous/1671882-using-either-the-bcr-abl-oncogene-or-the-erbb2-her2neu-oncogene-as-your-example-describe-one-specific-molecular-alteration-which-plays-a-role-in-cancer-development-and-discuss-how-it-has-been-exploited-to-improve-cancer-treatment
(Using Either the BCR-ABL Oncogene or the ERBB2 (HER2/NEU) Oncogene As Essay)
https://studentshare.org/miscellaneous/1671882-using-either-the-bcr-abl-oncogene-or-the-erbb2-her2neu-oncogene-as-your-example-describe-one-specific-molecular-alteration-which-plays-a-role-in-cancer-development-and-discuss-how-it-has-been-exploited-to-improve-cancer-treatment.
“Using Either the BCR-ABL Oncogene or the ERBB2 (HER2/NEU) Oncogene As Essay”, n.d. https://studentshare.org/miscellaneous/1671882-using-either-the-bcr-abl-oncogene-or-the-erbb2-her2neu-oncogene-as-your-example-describe-one-specific-molecular-alteration-which-plays-a-role-in-cancer-development-and-discuss-how-it-has-been-exploited-to-improve-cancer-treatment.
  • Cited: 0 times

CHECK THESE SAMPLES OF Specific Molecular Alteration in Cancer Development

Human Genome Project Using PCR

nnexin A5 has been implicated in a wide range of disease phenotypes and etiology including recurrent pregnancy losses and cancer.... The protein product of this gene has a molecular weight of approximately 35 kDa (Carcedo, Iglesias, Bances, Morgan & Fernandez, 2011)....
20 Pages (5000 words) Dissertation

The role of microRNAs in breast cancer

This has been observed in Tourette's syndrome, fragile X syndrome, and from recent research studies, associated with cancer development and progression (Kayani, Kayani, Malik & Faryal, 2011, p.... Recent investigations have targeted miRNAs because of their high possibility in solving problems in cancer therapy.... These include development of skeletal and heart muscles, and establishment and maintenance of cell lineage.... The miRNAs have the ability to express specific tissue, which has been, observed in insulin secretion, proliferation, hematopoiesis, adepocyte development, apoptosis, and brain pattering....
7 Pages (1750 words) Essay

Role of Gene Silencing in the Development of Cancer

Extensive research has led to the discovery of gene silencing and its role in cancer progression.... There are reports that alteration of certain genomes related to cancer suppression can result in silencing of genetic expression of these genes resulting in development of.... It has been proposed that detection of gene silencing in certain genes which are characteristic of tumors can help not only in early detection, but also may enhance the development of novel In this research, review of literature pertaining to gene silencing and development of cancer was conducted....
4 Pages (1000 words) Essay

Changes in protein glycosylation in cancer

This study explores proteins that alter glycosylation in cancer and how appropriate they serve the purpose of preventing the development of metastasis (secondary cancers).... The paper provides an overview of a complex topic on the mechanism of cellular glycosylation with a focus on the documented changes in protein glycosylation in cancer.... In this part, it is worth noting that the incomplete synthesis of the O-linked glycans, which involves changes in cancer-associated glycosylation, shall be highlighted alongside discussing the statistics of the possible associated functional significance of the cancer....
10 Pages (2500 words) Book Report/Review

How Variation Within the Human Genome Might Lead to Cancer

Through a multistep process, cells in cancer acquire a series of genetic variations or mutations that result in unrestrained division and growth of the cells, uninhibited differentiation of the cells, and evasion of programmed cell death (Wong et al, 2011: p428).... alteration in chromosome number also referred to as aneuploidy, is a critical characteristic of any cancer and is, in fact, one of the genetic alterations most observed in human cancers.... As a result, gene variations that over-activate proto-oncogenes and inhibit tumor suppressor genes drive the development of transformed cancer cells....
10 Pages (2500 words) Essay

Modern Era of Industrialization

hotosensitizer or photosensitizing agent is a molecule or a drug that is capable of producing a chemical alteration in another molecule or cell during the photochemical process.... Essential therapies for cancer involve chemotherapy and radiotherapy which have their own predicaments and may be perilous to health.... The phenomenon is exploited in photodynamic therapy to eliminate the side-effects imposed by other cancer therapeutic measures....
11 Pages (2750 words) Essay

The Role of Epigenetics in the Development and Progression of Cancer

The author states that epigenetics have a role not only in cancer biology but also in several fields like viral infections, cloning, and somatic gene therapy.... Epigenetic mechanisms involve changes in gene expression that are not only heritable but also occur without any alteration in the DNA sequences.... Das and Singal (2004) have defined epigenetics as a stable alteration in gene expression potential that takes place during development and cell proliferation, without any change in gene sequence....
10 Pages (2500 words) Literature review

Molecular Biology of Pancreatic Cancer

This work "Molecular Biology of Pancreatic cancer" describes the ductal adenocarcinoma of the pancreas as the fourth most devastating cause of the demise of cancer patients within the United States.... It has been approximated by 'The American cancer Society' that around thirty-seven thousand, one hundred and seventy United States residents were diagnosed with this specific type of cancer while around thirty-three thousand, three hundred and seventy died from it during 2007 (American cancer Society, 2007)....
10 Pages (2500 words) Essay
sponsored ads
We use cookies to create the best experience for you. Keep on browsing if you are OK with that, or find out how to manage cookies.
Contact Us